The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003.
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - Biothera; IGF Oncology; Medtronic; Superlab Far East; Vanquish Oncology
Consulting or Advisory Role - Superlab Far East; Vanquish Oncology
Travel, Accommodations, Expenses - Superlab Far East
 
R. Alejandro Sica
No Relationships to Disclose
 
Amer Sidani
No Relationships to Disclose
 
Gautam Gopalji Jha
Consulting or Advisory Role - Prometheus
 
Hui Xie
No Relationships to Disclose
 
Ajjai Shivaram Alva
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Research Funding - BIND Biosciences; Bristol-Myers Squibb; Genentech; Novartis; Oncogenex
 
Mark N. Stein
No Relationships to Disclose
 
Eric A. Singer
No Relationships to Disclose